Switch to:
More From Other Websites
Nektar Therapeutics Initiates Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell... Mar 27 2017
Trump is tapping Chris Christie to tackle the opioid epidemic — here's a fix scientists hope he'll... Mar 27 2017
4 Biotech Stocks to Watch Mar 22 2017
Nektar Therapeutics (NKTR): Here’s What Just Happened Mar 21 2017
Nektar's Pain Drug Positive in Phase III Study; Shares Gain Mar 21 2017
Stocks of Nektar Therapeutics and CytomX Therapeutics Rise on FDA Trial News Mar 21 2017
Biotech Hits 11-Year High On Potential To Dethrone Oxycodone Mar 20 2017
Nektar Pharma Opioid Drug Shows Promise In Phase 3 Mar 20 2017
Nektar, AMD, Esperion, and More: Here’s Why These Five Stocks Are Surging Mar 20 2017
A new painkiller is being designed that won't get users high, and it could save thousands of lives Mar 20 2017
Monday’s Top Biopharma Movers Mar 20 2017
Biotech Premarket Movers: CytomX, Aevi, Esperion Mar 20 2017
Nektar Therapeutics' stock jumps after positive results of its pain treatment drug Mar 20 2017
NEKTAR THERAPEUTICS Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 20 2017
Nektar's opioid painkiller succeeds in key late-stage study Mar 20 2017
NKTR-181 Meets Primary and Secondary Endpoints in Phase 3 SUMMIT-07 Study in Chronic Pain Mar 20 2017
Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study Mar 20 2017
Nektar Surges by Most Since 1996 After Opioid Trial Success Mar 20 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK